However, in the case of EZH2 (Figures 8(a)–8(c)), higher expression was obviously correlated with worse outcome in NSCLC patients (P < 0.001), and the situation was the same in pathologic TNM I (P=0.015) and II (P=0.01) NSCLC patients, while no survival difference had been found in pTNM-III NSCLC patients (P=1, Figure 8(d)). The gene discussed is EZH2; the disease is non-small cell lung carcinoma.